Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$229.22 -0.3%	$234.43	$149.04 ▼ $251.71	$553.66B	0.27	7.76 million shs	7.35 million shs
MRNA Moderna	$48.12 +5.2%	$51.16	$22.28 ▼ $59.55	$18.14B	1.05	7.97 million shs	4.77 million shs
NVAX Novavax	$9.27 +4.2%	$8.91	$6.13 ▼ $11.97	$1.46B	2.37	5.40 million shs	4.93 million shs
PFE Pfizer	$25.78 +0.5%	$26.91	$22.81 ▼ $28.75	$146.25B	0.35	38.68 million shs	35.52 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.33%	-0.52%	-0.56%	-7.16%	+49.25%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%
NVAX Novavax	+4.16%	+0.43%	+6.92%	+0.43%	+20.70%
PFE Pfizer	+0.44%	-0.69%	-6.41%	-4.07%	+9.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$229.22 -0.3%	$234.43	$149.04 ▼ $251.71	$553.66B	0.27	7.76 million shs	7.35 million shs
MRNA Moderna	$48.12 +5.2%	$51.16	$22.28 ▼ $59.55	$18.14B	1.05	7.97 million shs	4.77 million shs
NVAX Novavax	$9.27 +4.2%	$8.91	$6.13 ▼ $11.97	$1.46B	2.37	5.40 million shs	4.93 million shs
PFE Pfizer	$25.78 +0.5%	$26.91	$22.81 ▼ $28.75	$146.25B	0.35	38.68 million shs	35.52 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.33%	-0.52%	-0.56%	-7.16%	+49.25%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%
NVAX Novavax	+4.16%	+0.43%	+6.92%	+0.43%	+20.70%
PFE Pfizer	+0.44%	-0.69%	-6.41%	-4.07%	+9.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	10.39% Upside
MRNA Moderna	1.84	Reduce	$35.73	-25.74% Downside
NVAX Novavax	2.10	Hold	$12.13	30.80% Upside
PFE Pfizer	2.23	Hold	$28.84	11.89% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRNA, JNJ, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/13/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
5/13/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00
5/7/2026	NVAX Novavax	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/6/2026	NVAX Novavax	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$8.00 ➝ $9.00
5/4/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$36.00 ➝ $45.00
5/4/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$35.00 ➝ $38.00
5/1/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$43.00 ➝ $49.00
5/1/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
4/29/2026	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00

(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	5.86	$14.07 per share	16.29	$33.73 per share	6.80
MRNA Moderna	$1.94B	9.82	N/A	N/A	$18.67 per share	2.58
NVAX Novavax	$1.12B	1.36	$3.65 per share	2.54	($0.88) per share	-10.53
PFE Pfizer	$62.58B	2.35	$4.41 per share	5.84	$15.86 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.65	26.50	18.22	2.25	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)
NVAX Novavax	$440.30M	-$0.58	N/A	N/A	N/A	-14.73%	-14.82%	1.23%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.68	9.01	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest PFE, MRNA, JNJ, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVAX Novavax	-$0.25	-$0.06	+$0.19	-$0.06	$79.81 million	$118.90 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion
2/26/2026	Q4 2025	NVAX Novavax	-$0.66	$0.11	+$0.77	$0.11	$90.26 million	$136.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	2.27%	+5.25%	60.12%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.67%	-13.20%	131.30%	16 Years

Latest PFE, MRNA, JNJ, and NVAX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.46	1.03	0.77
MRNA Moderna	0.08	2.41	2.35
NVAX Novavax	N/A	2.48	2.45
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRNA Moderna	10.80%
NVAX Novavax	1.00%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
NVAX Novavax	1,990	164.44 million	162.79 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

PFE, MRNA, JNJ, and NVAX Headlines

Recent News About These Companies

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

May 20 at 3:19 PM | finance.yahoo.com

Pfizer Advances Pneumonia Vaccine After 15-Fold Antibody Response Data

May 20 at 3:19 PM | finance.yahoo.com

FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer

May 20 at 1:01 PM | seekingalpha.com

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

May 20 at 11:46 AM | zacks.com

Pfizer begins late-stage trial for new pneumococcal shot in infants after strong phase 2 data

May 20 at 10:19 AM | msn.com

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

May 20 at 10:10 AM | investors.com

Pfizer Expands Pneumococcal Vaccine Push With New Programs

May 20 at 9:30 AM | benzinga.com

Pfizer Inc. $PFE Shares Acquired by Marble Harbor Investment Counsel LLC

May 20 at 5:50 AM | marketbeat.com

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20 at 5:08 AM | reuters.com

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20 at 5:05 AM | businesswire.com

Pfizer Inc. stock outperforms competitors on strong trading day

May 19 at 11:19 PM | marketwatch.com

Pfizer (NYSE:PFE) Trading Up 1.3% - Should You Buy?

May 19 at 5:39 PM | marketbeat.com

Is Pfizer Inc. (PFE) Stock a Good Investment?

May 19 at 1:18 PM | aaii.comA

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

May 19 at 1:18 PM | 247wallst.com

Julia B. Fee Sotheby's International Realty Names Katie Brunner Brokerage Manager of Bedford, N.Y., Office

May 19 at 1:18 PM | finance.yahoo.com

Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial

May 19 at 12:51 PM | tipranks.com

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

May 19 at 12:38 PM | 247wallst.com

Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

May 19 at 10:46 AM | 247wallst.com

GSA Capital Partners LLP Acquires 124,411 Shares of Pfizer Inc. $PFE

May 19 at 4:31 AM | marketbeat.com

[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

May 18 at 12:44 AM | finance.yahoo.com

PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

May 18 at 1:10 PM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, MRNA, JNJ, and NVAX Company Descriptions

Johnson & Johnson NYSE:JNJ

$229.22 -0.78 (-0.34%)

Closing price 05/20/2026 03:59 PM Eastern

Extended Trading

$229.45 +0.23 (+0.10%)

As of 05/20/2026 07:55 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$48.12 +2.40 (+5.25%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$48.09 -0.03 (-0.06%)

As of 05/20/2026 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$9.27 +0.37 (+4.16%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$9.31 +0.04 (+0.46%)

As of 05/20/2026 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$25.78 +0.12 (+0.46%)

Closing price 05/20/2026 03:59 PM Eastern

Extended Trading

$25.79 +0.01 (+0.05%)

As of 05/20/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRNA, JNJ, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRNA, JNJ, and NVAX Earnings

Compare Dividends

Latest PFE, MRNA, JNJ, and NVAX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRNA, JNJ, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, MRNA, JNJ, and NVAX Company Descriptions

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRNA, JNJ, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRNA, JNJ, and NVAX Earnings

Compare Dividends

Latest PFE, MRNA, JNJ, and NVAX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRNA, JNJ, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, MRNA, JNJ, and NVAX Company Descriptions

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools